ArticleJournal of clinical medicine2022
Significance of Temporal Muscle Thickness in Chronic Subdural Hematoma.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Value of temporal muscle thickness in predicting outcomes of stroke: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Temporal Muscle Thickness Is a Prognostic Factor for Neurological Recovery After Surgery for Chronic Subdural Hematoma.Diagnostics (Basel, Switzerland) · 2026Article
- Age- and sex-adjusted CT-based reference values for temporal muscle thickness, cross-sectional area and radiodensity.Scientific reports · 2025Article
- Difference among frailty assessment tools in predicating postoperative prognosis of elderly patients with mild traumatic brain injury.Clinics (Sao Paulo, Brazil) · 2025Article
- Prognostic value of temporalis muscle thickness as a marker of sarcopenia in intracerebral hemorrhage.Frontiers in neurology · 2025Article
- Predictive value of temporal muscle thickness in patients with chronic subdural hematoma.Frontiers in neurology · 2025Article
- Reduced temporal muscle thickness predicts shorter survival in patients undergoing chronic subdural haematoma drainage.Journal of cachexia, sarcopenia and muscle · 2024Article
- Synthetic minority over-sampling technique-enhanced machine learning models for predicting recurrence of postoperative chronic subdural hematoma.Frontiers in neurology · 2024Article
- Frailty in Traumatic Brain Injury-The Significance of Temporal Muscle Thickness.Journal of clinical medicine · 2023Article
- Advances in Musculoskeletal Imaging and Their Applications.Journal of clinical medicine · 2023Article
- Initial Temporal Muscle Thickness and Area: Poor Predictors of Neurological Outcome in Aneurysmal Subarachnoid Hemorrhage in a Central European Patient Cohort.Journal of clinical medicine · 2023Article
- Frailty in cerebellar ischemic stroke-The significance of temporal muscle thickness.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reduced temporal muscle thickness (TMT) was verified as an independent negative prognostic parameter for outcome in brain tumor patients. Independent thereof, chronic subdural hematoma (CSDH) is a neurosurgical condition with high recurrence rates and unreliable risk models for poor outcome. Since sarcopenia was associated with poor outcome, we investigated the possible role of TMT and the clinical course of CSDH patients. Methods: This investigation is a single-center retrospective study on patients with CSDH. We analyzed the radiological and clinical data sets of 171 patients with surgically treated CSDH at a University Hospital from 2017 to 2020. Results: Our analysis showed a significant association between low-volume TMT and increased hematoma volume (p < 0.001), poor outcome at discharge (p < 0.001), and reduced performance status at 3 months (p < 0.002). Conclusion: TMT may represent an objective prognostic parameter and assist the identification of vulnerable CSDH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.